Vitiligo futures

CLINUVEL is evaluating the use of afamelanotide as an investigational therapy for repigmentation in vitiligo.

If you or a loved one has vitiligo, follow our progress at clinuvel.com/vitiligo, or sign up below to receive updates.

SCENESSE® (afamelanotide 16mg) is CLINUVEL’s proprietary first-in-class photoprotective drug that has been approved in the USA (2019), Europe (2014), and Australia (2020) for use in adult patients with erythropoietic protoporphyria (EPP).

Register your interest to learn more

Email address*

Confirm Email address*

Title*

First name*

Family name*

Telephone number*

Location*

State/province*

Zip code*

I confirm that I give CLINUVEL permission to store necessary information and share it with third parties for the purpose of enrolling in a clinical trial. I also consent to being contacted regarding participation in CLINUVEL's vitiligo program. I understand that I can withdraw my permission at any time by emailing clinicaltrials@clinuvel.com.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Register your interest to learn more

Vitiligo

About CLINUVEL